"Institutul Oncologic „Prof. Dr. Alexandru Trestioreanu" Bucureşti asigură servicii medicale de screening, diagnostic, curative şi paliative în domeniul oncologic desfăşurând totodată o amplă activitate de învăţământ, cercetare, studii clinice, cu participare la derulare şi implementare a proiectelor din programele de finanţare europeană."

During the past decade, Institutul Oncologic Prof. Dr. Al. Trestioreanu Bucuresti conducted 11 clinical trials. In the 10-year time frame, 11 clinical trials started and 18 clinical trials were completed, i.e. on average, 163.6% percent of trials that started reached the finish line to date. In the past 5 years, 1 clinical trials started and 8 clinical trials were completed. i.e. 800% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Institutul Oncologic Prof. Dr. Al. Trestioreanu Bucuresti" #1 sponsor was "Hoffmann-La Roche" with 12 trials, followed by "Central European Cooperative Oncology Group" with 3 trials sponsored, "Boehringer Ingelheim" with 2 trials sponsored, "Eli Lilly and Company" with 2 trials sponsored and "European Organisation for Research and Treatment of Cancer - EORTC" with 2 trials sponsored. Other sponsors include 7 different institutions and companies that sponsored additional 16 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Institutul Oncologic Prof. Dr. Al. Trestioreanu Bucuresti" #1 collaborator was "Australasian Lung Cancer Trials Group" with 1 trials as a collaborator, "Canadian Cancer Trials Group" with 1 trials as a collaborator, "Central and Eastern European Oncology Group" with 1 trials as a collaborator, "Chinese Thoracic Oncology Group" with 1 trials as a collaborator and "Dutch Society of Physicians for Pulmonology and Tuberculosis" with 1 trials as a collaborator. Other collaborators include 4 different institutions and companies that were collaborators in the rest 14 trials.

According to Clinical.Site data, the most researched conditions in "Institutul Oncologic Prof. Dr. Al. Trestioreanu Bucuresti" are "Breast Cancer" (4 trials), "Bladder Cancer" (2 trials), "Carcinoma, Non-Small-Cell Lung" (2 trials), "Non-Small Cell Lung Cancer" (2 trials) and "Prostate Cancer" (2 trials). Many other conditions were trialed in "Institutul Oncologic Prof. Dr. Al. Trestioreanu Bucuresti" in a lesser frequency.

Most popular intervention types in "Institutul Oncologic Prof. Dr. Al. Trestioreanu Bucuresti" are "Drug" (31 trials), "Other" (3 trials), "Biological" (2 trials) and "Radiation" (1 trials). Other intervention types were less common.

The name of intervention was led by "Paclitaxel" (6 trials), "Placebo" (6 trials), "Carboplatin" (4 trials), "Docetaxel" (3 trials) and "Atezolizumab" (2 trials). Other intervention names were less common.

The vast majority of trials in "Institutul Oncologic Prof. Dr. Al. Trestioreanu Bucuresti" are 28 trials for "All" genders, 3 trials for "Female" genders and 2 trials for "Male" genders.

Currently, there are NaN active trials in "Institutul Oncologic Prof. Dr. Al. Trestioreanu Bucuresti". undefined are not yet recruiting, 1 are recruiting, 6 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 22 completed trials in Institutul Oncologic Prof. Dr. Al. Trestioreanu Bucuresti, undefined suspended trials, and 4 terminated clinical trials to date.

Out of the total trials that were conducted in Institutul Oncologic Prof. Dr. Al. Trestioreanu Bucuresti, 1 "Phase 1" clinical trials were conducted, 9 "Phase 2" clinical trials and 22 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".